Skip to content

Author

Douglas K. Marks

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Phase II study of pembrolizumab plus nab-paclitaxel in Hormone Receptor–positive, HER2- negative metastatic breast cancer: clinical and molecular insights into response

Abstract Purpose We investigate the addition of PD-1 blockade to chemotherapy in HR + MBC to assess efficacy, safety, and changes in the tumor microenvironment utilizing serial tumor biopsies. Methods Single-arm phase 2 clinical trial (NCT02752685) of 20 HR+/HER2- MBC patients received nab-paclitaxel (100mg/m2 IV d1/8,...

N. Klar, J. Goldberg, Apoorvi Tyagi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.